NASDAQ:BGNE - Beigene Stock Price, News & Analysis

$130.90
-2.22 (-1.67 %)
(As of 09/19/2019 06:47 AM ET)
Today's Range
$128.35
Now: $130.90
$131.77
50-Day Range
$120.61
MA: $136.69
$147.11
52-Week Range
$105.19
Now: $130.90
$179.57
Volume311,465 shs
Average Volume389,915 shs
Market Capitalization$6.22 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.02
BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer in the People's Republic of China, the United States, and internationally. Its commercial products include ABRAXANE, a chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancers; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BGNE
CUSIPN/A
Phone1-345-949-4123

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$198.22 million
Book Value$29.52 per share

Profitability

Net Income$-673,770,000.00
Net Margins-153.32%

Miscellaneous

Employees2,070
Market Cap$6.22 billion
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable

Receive BGNE News and Ratings via Email

Sign-up to receive the latest news and ratings for BGNE and its competitors with MarketBeat's FREE daily newsletter.


Beigene (NASDAQ:BGNE) Frequently Asked Questions

What is Beigene's stock symbol?

Beigene trades on the NASDAQ under the ticker symbol "BGNE."

How were Beigene's earnings last quarter?

Beigene Ltd (NASDAQ:BGNE) announced its quarterly earnings results on Thursday, August, 8th. The company reported ($1.43) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($3.01) by $1.58. The business had revenue of $243.35 million for the quarter, compared to analyst estimates of $65.58 million. Beigene had a negative return on equity of 38.41% and a negative net margin of 153.32%. The company's quarterly revenue was up 360.8% on a year-over-year basis. During the same quarter in the previous year, the company earned ($2.92) EPS. View Beigene's Earnings History.

When is Beigene's next earnings date?

Beigene is scheduled to release their next quarterly earnings announcement on Wednesday, November 6th 2019. View Earnings Estimates for Beigene.

What price target have analysts set for BGNE?

10 brokers have issued 1-year price objectives for Beigene's stock. Their predictions range from $160.75 to $215.00. On average, they expect Beigene's stock price to reach $185.75 in the next twelve months. This suggests a possible upside of 41.9% from the stock's current price. View Analyst Price Targets for Beigene.

What is the consensus analysts' recommendation for Beigene?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Beigene in the last year. There are currently 1 sell rating and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Beigene.

Has Beigene been receiving favorable news coverage?

Media headlines about BGNE stock have been trending negative recently, according to InfoTrie Sentiment. The research firm identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Beigene earned a news impact score of -2.9 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the next several days. View News Stories for Beigene.

Who are some of Beigene's key competitors?

What other stocks do shareholders of Beigene own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Beigene investors own include Alibaba Group (BABA), NVIDIA (NVDA), AbbVie (ABBV), Crispr Therapeutics (CRSP), Gilead Sciences (GILD), GW Pharmaceuticals PLC- (GWPH), ACADIA Pharmaceuticals (ACAD), Adobe (ADBE), Celgene (CELG) and Exelixis (EXEL).

Who are Beigene's key executives?

Beigene's management team includes the folowing people:
  • Mr. John V. Oyler, Co-Founder, CEO & Chairman (Age 51)
  • Dr. Xiaodong Wang, Co-Founder, Chairman of the Scientific Advisory Board & Director (Age 56)
  • Dr. Heng Liang, CFO & Chief Strategy Officer (Age 56)
  • Dr. Jane E. Huang M.D., Chief Medical Officer - Hematology (Age 46)
  • Dr. Xiaobin Wu, Pres & Gen. Mang. of China

When did Beigene IPO?

(BGNE) raised $126 million in an IPO on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at a price of $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company served as the underwriters for the IPO and Baird was co-manager.

Who are Beigene's major shareholders?

Beigene's stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (4.31%), BlackRock Inc. (4.24%), Vanguard Group Inc. (2.66%), Price T Rowe Associates Inc. MD (1.59%), Artal Group S.A. (1.39%) and Northern Trust Corp (1.28%). Company insiders that own Beigene stock include Amy C Peterson, Bros Advisors Lp Baker, Donald W Glazer, Howard Liang, Jane Huang, Ji Li, John Oyler, Timothy Yung-Cheng Chen, Xiaobin Wu and Xiaodong Wang. View Institutional Ownership Trends for Beigene.

Which major investors are selling Beigene stock?

BGNE stock was sold by a variety of institutional investors in the last quarter, including Canada Pension Plan Investment Board, Victory Capital Management Inc., Russell Investments Group Ltd., Morgan Stanley, Price T Rowe Associates Inc. MD, Allianz Asset Management GmbH, Bank of America Corp DE and Discovery Value Fund. Company insiders that have sold Beigene company stock in the last year include Amy C Peterson, Donald W Glazer, Howard Liang, Jane Huang, John Oyler, Timothy Yung-Cheng Chen, Xiaobin Wu and Xiaodong Wang. View Insider Buying and Selling for Beigene.

Which major investors are buying Beigene stock?

BGNE stock was bought by a variety of institutional investors in the last quarter, including Myriad Asset Management Ltd., Invesco Ltd., New Silk Road Investment PTE Ltd., BlackRock Inc., BlackRock Inc., Nuveen Asset Management LLC, Matthews International Capital Management LLC and Janus Henderson Group PLC. View Insider Buying and Selling for Beigene.

How do I buy shares of Beigene?

Shares of BGNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Beigene's stock price today?

One share of BGNE stock can currently be purchased for approximately $130.90.

How big of a company is Beigene?

Beigene has a market capitalization of $6.22 billion and generates $198.22 million in revenue each year. The company earns $-673,770,000.00 in net income (profit) each year or ($12.15) on an earnings per share basis. Beigene employs 2,070 workers across the globe.View Additional Information About Beigene.

What is Beigene's official website?

The official website for Beigene is http://www.beigene.com/.

How can I contact Beigene?

Beigene's mailing address is 94 SOLARIS AVENUE CAMANA BAY, GRAND CAYMAN E9, KY1-1108. The company can be reached via phone at 1-345-949-4123 or via email at [email protected]


MarketBeat Community Rating for Beigene (NASDAQ BGNE)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  402 (Vote Outperform)
Underperform Votes:  323 (Vote Underperform)
Total Votes:  725
MarketBeat's community ratings are surveys of what our community members think about Beigene and other stocks. Vote "Outperform" if you believe BGNE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BGNE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel